Molecular Imaging, Pharmacokinetics, and Dosimetry of111In-AMBA in Human Prostate Tumor-Bearing Mice

Abstract

Molecular imaging with promise of personalized medicine can provide patient-specific information noninvasively, thus enabling treatment to be tailored to the specific biological attributes of both the disease and the patient. This study was to investigate the characterization of DO3A-CH2CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-NH2(AMBA)in vitro, MicroSPECT/CT imaging, and biological activities of111In-AMBA in PC-3 prostate tumor-bearing SCID mice. The uptake of111In-AMBA reached highest with3.87±0.65% ID/g at 8 h. MicroSPECT/CT imaging studies suggested that the uptake of111In-AMBA was clearly visualized between 8 and 48 h postinjection. The distribution half-life (t1/2α) and the elimination half-life (t1/2β) of111In-AMBA in mice were 1.53 h and 30.7 h, respectively. TheCmax⁡and AUC of111In-AMBA were 7.57% ID/g and 66.39 h∗% ID/g, respectively. The effective dose appeared to be 0.11 mSv/MBq-1. We demonstrated a good uptake of111In-AMBA in the GRPR-overexpressed PC-3 tumor-bearing SCID mice.111In-AMBA is a safe, potential molecular image-guided diagnostic agent for human GRPR-positive tumors, ranging from simple and straightforward biodistribution studies to improve the efficacy of combined modality anticancer therapy.